Start prescribing Omnipod® 5 with confidence
Prescribing Omnipod® 5 may help to improve glycaemic control and ease the burden of type 1 diabetes (T1D) care*1-3
Making the change to automated insulin delivery (AID) with Omnipod 5 shouldn’t be a challenge for you or your patients. See how it could help to improve T1D control for your patients from 2 years of age, with a system that adjusts to their insulin needs and supports them every step of the way.
*Results from two pivotal single-arm, multicentre, prospective studies in participants with T1D aged 6–70 years (112 children aged 6–13.9 years and 129 adolescents/adults aged 14–70 years) and 80 very young children with T1D (2.0–5.9 years).1,2
Flexibility for patient choice:
Omnipod 5 Pods are partially subsidised and listed on the NDSS. Access to Omnipod 5 is available with private health insurance similar to other insulin pump systems; OR by paying a no lock-in subscription fee (Pay as you Pod) to Insulet Australia.
Everything you need to know about prescribing Omnipod® 5
Supporting healthcare professionals and their patients every step of the way
Omnipod Clinical Specialists are on hand to introduce people with T1D to Pod Therapy, and to answer any questions that they, or you, may have.
Direct your patients to watch a virtual Live Demo webinar to learn more.
See webinars & virtual product demos:
We also offer a variety of resources for Pod Therapy education and start up:
- How-to videos, resources and more
- Your patients can experience the comfort and convenience of the Pod first-hand with the Pod Experience Kit, which includes a needle-free Demo Pod that does not deliver insulin (The Omnipod 5 Controller and/or Omnipod DASH PDM are not included)
What the Omnipod® 5 System provides for your patients and practice
Omnipod 5 is an on-body, tubeless AID system with a built-in algorithm that communicates directly with the CGM sensor and Controller to inform automated insulin dosing.2
Omnipod 5 puts simplified T1D management into your patients’ hands. At its heart is SmartAdjust™ technology, proactively managing insulin delivery every 5 minutes using a personalised glucose target to help minimize time in hyperglycaemia and hypoglycaemia.1,2,*,†
Get up-to-date patient data to evaluate their progress with the Glooko® platform, which enables wireless data uploads to support remote and in-person care. Support treatment decisions with actionable insights that combine sensor and insulin data, with rapid identification of trends for personalised care.
Choosing an insulin for Omnipod® 5
Rapid-acting U-100 insulins compatible with Omnipod 5—prescribe the one that’s right for your patient.
The following insulins have been tested and found safe for use with Omnipod 5:
- NovoLog®/NovoRapid®
- Humalog®/Liprolog®
- Admelog®/Insulin lispro Sanofi®
- Trurapi®/Insulin aspart Sanofi®
- Kirsty®.
Which patients may benefit from switching to Omnipod® 5?
Patients who find diabetes management complex
Simplify Life® with Omnipod 5 Automated Insulin Delivery, incorporating a Dexcom G6, Dexcom G7, or FreeStyle Libre 2 Plus sensor and SmartAdjust™ technology alrorithm to make effective T1D care an achievable goal.
Patients struggling to maintain glycaemic control
Omnipod 5 delivered significant improvements vs prior therapy (Multiple Daily Injection [MDI] or Continuous Subcutaneous Insulin Infusion [CSII]) in A1c and Time in Range (TIR) for users aged 2 years and older in clinical trials.1,2
Patients who feel burdened by diabetes management
Help your patients realise the freedom and flexibility of on-body, personalised, adaptive T1D control. Using Omnipod® 5 has been shown to decrease diabetes distress, potentially helping to ease the substantial burden of T1D management.3
Prescribing Omnipod 5 for children
- Adjusting over time to your young patients’ insulin needs, with SmartAdjust™ technology to help protect them against highs and lows,†
- Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so children can continue their AID when swimming or bathing
- Improved glycaemic outcomes that go hand-in-hand with improved quality of life and mental well-being reported by parents of children with T1D1-4
Prescribing Omnipod® 5 for adults
- Adjusting over time to your patients’ needs, with SmartAdjust™ technology to help to protect them against highs and lows*†
- Tubeless, waterproof‡, on-body, Automated Insulin Delivery (AID), so that adults can live their lives without interrupting their AID
- Improved glycaemic outcomes that go hand-in-hand with improved patient-reported outcomes such as diabetes distress and stress when eating1,2
How to get started
To help you and your patients start Omnipod® 5 with ease, we offer a variety of live and online educational and support resources.
Be the first to know
Stay up to date and be in the know when it comes to all things Insulet. Subscribe for healthcare professional updates: training and events, Omnipod published data and first-hand experiences from Podders.
Follow Omnipod on MyINTERACT for resources and educational materials as well.
†If glucose alerts and readings from the sensor do not match symptoms or expectations, a blood glucose meter should be used to make diabetes treatment decisions.
‡The Pod has an IP28 rating for up to 7.6 metres (25 feet) for up to 60 minutes. The Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.
§Terms and conditions apply. Eligibility may vary. Click on Omnipod Innovation Pathway for full terms.
¶When covered by public and private payors.
References:
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents and children as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, p<0.0001 and ST = 52.5%, 3-mo Omnipod 5 = 68.0%, p<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, p<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), p<0.0001). Mean time in hypoglycaemic range in adults/adolescents and children (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3-mo Omnipod 5 = 1.32%, p<0.0001 and 2.21%, 3-mo Omnipod 5 = 1.78%, p<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (p<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, p<0.0001. Mean time in hypoglycaemic range (<3.9mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, p<0.0001.
3. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. During the Omnipod 5 pivotal trial, adults aged 18-70 (N=115) experienced an improved diabetes distress survey score after 3 months of AID use: mean: 1.48 vs. 1.64 (p< 0.001).
4. Hood KK, et al. Pediatric Diabetes 2023. During the Omnipod 5 pivotal trial, parents of children aged 6-11.9 years (N=82) experienced an improvement in emotional distress levels and mental well-being survey scores after 3 months of Omnipod 5 use compared to standard therapy: mean P-PAID-C score = 40.7 vs. 47.4; mean WHO-5 score = 72.9 vs. 67.5, respectively.